Semaglutide linked to 15% lower fracture risk in diabetes cohort
Retrospective analysis of nearly 60,000 patients was presented at ENDO 2026 in Chicago and has not been peer reviewed.
PR
By Priya Raman · Science Reporter
Jun 16 03:00 ETSource: ScienceDaily
The wire
- 01Stanford-led researchers compared 26,324 semaglutide users with 33,555 patients on dulaglutide, phentermine/topiramate or bupropion/naltrexone, recording 794 versus 1,045 fractures despite greater BMI reduction on semaglutide.
- 02The finding runs counter to concerns that rapid GLP-1 weight loss thins bone, and the authors urge bone-health monitoring within weight-loss programs.
- 03The study is a retrospective electronic health record analysis covering 2016 to 2023, presented as a conference abstract; investigators say prospective studies are needed to confirm the association.
From the source
Read at sciencedaily.comSemaglutide (Ozempic) linked to fewer bone fractures despite greater weight loss
A new study suggests that semaglutide (Ozempic, Wegovy, Rybelsus) may offer an unexpected benefit for people with type 2 diabetes. Researchers found that patients taking the medication experienced fewer bone fractures and greater weight loss than those using several other anti-obesity treatments.